SIRT7 Controls T Cell Cancer-Fighting Power via Amino Acid and Fat Metabolism
Deleting SIRT7 in T cells disrupts branched-chain amino acid and fatty acid metabolism, impairing antitumor immunity and accelerating T cell exhaustion.
Summary
Researchers discovered that SIRT7, a mitochondria-associated enzyme, governs T cell antitumor function by regulating branched-chain amino acid (BCAA) catabolism and fatty acid synthesis. In mice lacking SIRT7 specifically in T cells, BCAA metabolites and fatty acids accumulate, reducing cytotoxic cytokine output (notably IFN-γ) and accelerating T cell exhaustion. Mechanistically, SIRT7 desuccinylates key BCAA catabolic enzymes, keeping their activity in check. Inhibiting BCAA catabolism pharmacologically or removing dietary BCAAs rescued T cell function, while adding fatty acids worsened it. These findings position SIRT7 as a metabolic checkpoint linking nutrient sensing to cancer immunity.
Detailed Summary
**Why this matters:** T cells are the immune system's primary cancer killers, but their function depends on tightly regulated metabolic programs. Understanding how epigenetic and post-translational mechanisms tune T cell metabolism could unlock new immunotherapy strategies, particularly for patients who respond poorly to current checkpoint inhibitors.
**What was studied:** The researchers focused on SIRT7, the least characterized member of the Sirtuin family of NAD⁺-dependent deacylases. Using whole-body Sirt7 knockout (Sirt7⁻/⁻) and T cell-specific conditional knockout mice (Sirt7^fl/fl Cd4-Cre), they performed proteomics, lysine succinylome, and acetylome profiling on spleen tissue to map SIRT7's substrates and downstream metabolic consequences.
**Key results:** SIRT7 is highly expressed in immune tissues, particularly in adaptive immune cells including T cells, and partially localizes to mitochondria. Succinylome analysis revealed that loss of SIRT7 leads to hypersuccinylation of enzymes in the BCAA catabolism pathway (e.g., branched-chain keto acid dehydrogenase complex components), enhancing their activity. This drives excess acyl-CoA production and increased fatty acid synthesis. In T cell-specific knockout mice, BCAA metabolites and fatty acids accumulate, resulting in reduced IFN-γ secretion, impaired proliferation and activation, and accelerated exhaustion. Importantly, two rescue strategies—treatment with BT2 (a BCKDK inhibitor that reduces BCAA flux) or a BCAA-free diet—alleviated T cell dysfunction, while exogenous fatty acid supplementation exacerbated it, confirming the metabolic axis as causal.
**Implications:** SIRT7 acts as a molecular brake on BCAA catabolism through protein desuccinylation, thereby preventing downstream lipid overload that undermines T cell effector function. This positions SIRT7 as a novel metabolic checkpoint in antitumor immunity. Therapeutic strategies that boost SIRT7 activity in T cells, or that reduce BCAA catabolism pharmacologically, could enhance the efficacy of cancer immunotherapy. The study also expands the functional map of lysine succinylation as a regulatory modification in immune metabolism.
**Caveats:** The study relies primarily on mouse models, and translation to human T cell biology requires validation. The full scope of SIRT7's desuccinylation targets beyond BCAA enzymes remains incompletely defined, and the relative contribution of acetylation versus succinylation to SIRT7's immunological functions needs further delineation.
Key Findings
- SIRT7 deficiency causes hypersuccinylation of BCAA catabolic enzymes, boosting their activity in mitochondria.
- Loss of SIRT7 in T cells accumulates BCAA metabolites and fatty acids, reducing IFN-γ and cytotoxic function.
- T cell-specific Sirt7 knockout mice show impaired proliferation, activation, and accelerated exhaustion.
- BT2 (BCKDK inhibitor) or BCAA-free diet rescues T cell antitumor function in Sirt7-deficient mice.
- Exogenous fatty acid treatment worsens T cell dysfunction, confirming lipid overload as a key driver.
Methodology
The study used whole-body and T cell-specific (Cd4-Cre) Sirt7 knockout mouse models alongside spleen proteomics, lysine succinylome, and acetylome profiling to identify SIRT7 substrates. Functional T cell assays, tumor models, dietary interventions (BCAA-free diet), and pharmacological tools (BT2 inhibitor, fatty acid supplementation) were employed to establish causality.
Study Limitations
Findings are based on mouse models and may not directly translate to human T cell biology without further validation. The complete lysine succinylation substrate landscape of SIRT7 beyond BCAA enzymes remains to be fully characterized. Distinguishing the independent contributions of SIRT7's deacetylase versus desuccinylase activities to immune phenotypes requires additional mechanistic dissection.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: